YKL-40 in health and disease: a challenge for joint inflammation by Kazakova, Maria & Sarafian, Victoria
Received 25 November 2013, revised 5 December 2013, accepted 10 December 2013. 
Correspondence to Dr Victoria Sarafian, Department of Medical Biology, Medical University, 15a V. Aprilov Blvd, 
Plovdiv-4002, Bulgaria. Tel.: +359 888 13 73 86, E-mail: sarafian@abv.bg
© Bul garian Society for Cell Biology
ISSN 1314-1929 (online)
Biomedical Reviews 2013; 24: 49-56
YKL-40 in heaLth and disease: a chaLLenge for joint infLammation
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There is a need of biomarkers to detect early joint inflammation and destruction of cartilage in different types of arthritis. YKL-
40, a 39 kD heparin- and chitin-binding secreted glycoprotein (also known as cartilage gp39), was recently discovered. Its 
exact biological function is still unclear.  Specific receptors for YKL-40 have not been identified yet. The clinical significance of 
YKL-40 as a biomarker is discussed in different aspects.  High level of YKL-40 was found in various human diseases associated 
with inflammatory and neoplastic processes. The review highlights the information available about YKL-40 and its significance 
in inflammatory joint diseases. We suggest that this glycoprotein might have a promising value as a novel biomarker and could 
provide additional evidence for inflammation activity in different types of arthritis. Biomed Rev 2013, 24: 49-56
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introdUction 
Rheumatic joint diseases are common disorders that affect a 
large part of the human population. They are associated with 
progressive disability, early death and socioeconomic costs (1). 
Some of them are manifested as acute or degenerative inflam-
matory arthritis. Almost all types of arthritis are characterized 
by destruction of articular tissue, synovial inflammation and 
angiogenesis, bone and cartilage loss (2).
Lots of research efforts are made to identify a biomarker, 
which alone or in combination with other conventional markers 
could be useful for diagnosis and monitoring of these diseases.
YKL-40, a 39 kD heparin- and chitin-binding glycoprotein, 
is a novel potential biomarker of inflammatory processes, 
which is expressed and secreted by immune cells such as 
activated macrophages and neutrophils (3). Several studies 
indicate that secretion levels of this glycoprotein are elevated 
in rheumatoid arthritis (4), osteoarthritis (5), heart failure (6), 
asthma and chronic obstructive pulmonary diseases (7). In 
addition, independent investigations reveal that high serum 
YKL-40 levels are correlated with aggressiveness and poor 
survival in different malignancies such as glioblastoma (8), 
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ovarian cancer (9), breast and colorectal cancer (10,11). 
Despite of these evidences some authors disagree with the 
significance of YKL-40 in inflammatory and neoplastic 
processes (12). 
The present review focuses on the importance of YKL-40 
in inflammatory joint diseases and on its value as a diagnostic 
or prognostic marker for disease activity.
YKL-40: gene and Protein 
YKL-40 contains a single polypeptide chain, comprising of 383 
amino acids and has a molecular mass of 40 kD (13,14). Amino 
acid sequencing showed that it belongs to the glycosyl hydro-
lase family 18 (15). This family includes enzymes and pro-
teins, chitinases from different species (mammalian, bacteria, 
fungi, nematodes, insects and plants) (16). All “mammalian 
chitinase-like proteins” show a high level of sequence identity 
over certain regions. The N-terminal amino acid sequence and 
the catalytic center are highly conserved (>70% identical), 
whereas the identities are low in the C-terminal sequence. 
It has also been demonstrated that Drosophila melanogaster 
secretes several proteins with sequence identity to YKL-40 
(16-34%). The nematode Caenorhabditis elegans and the zebra 
fish Danio rerio have multiple putative YKL-40-like proteins 
(18%-30%) with sequence identity (3). 
Two mutations of the catalytic glutamic and aspartic acids 
to leucine and to alanine respectively are responsible for the 
lack of hydrolase activity of YKL-40 (17). The human YKL-
40 gene is located on chromosome 1q32.1 and consists of 
10 exons (18). A study on the transcriptional regulation of 
YKL-40 during human macrophage differentiation suggests 
that the YKL-40 gene in monocytes is inactived and requires 
additional events to initiate promoter activity. The promoter 
sequence contains binding sites for several known factors. The 
Sp1-family transcription factor has a major role in controlling 
YKL-40 promoter activity (18).
The crystallographic structure of human YKL-40 exhibits 
two globular domains, which form a groove and correspond 
to the active cite of the protein (15). 
YKL-40: regULation and BioLogicaL fUnction
Few data is available about the regulation of YKL-40, and 
these are quite contradictory. YKL-40 secretion in freshly 
isolated chondrocytes is stimulated by interleukin (IL-6, IL-
17, IL-18) and tumor necrosis factor-alpha (TNF-α) (19-21). 
Insulin-growth factor-I (IGF-I) and insulin-growth factor-II 
(IGF-II) induce YKL-40 secretion in guinea pig chondrocytes 
but not in human chondrocytes (20,22). Most probably, the 
results might be due to differenices in the investigated species. 
Some authors determined that hypoxia and ionizing radiation 
activated YKL-40 secretion in glioblastoma cell lines - U87, 
U118, U373, while fibroblast growth factor (FGF) and TNF-α 
suppressed the glycoprotein production (23). 
Zhang et al revealed that resveratrol inhibited YKL-40 
expression by influencing its promoter activity and mRNA 
transcription levels in U87 cells in in vitro conditions (24). 
Other researchers showed that IL-1β was the potential inducer 
of astrocytic YKL-40 transcription. The proinflammatory 
interleukins such as IL-2, IL-6, IL-12, IL-13, IL-17 and IL-18 
did not induce YKL-40 transcription in astrocytes (25). The 
summarized data about known inducers and suppressors of 
YKL-40 secretion is presented in Figure 1.
These contradictory results emphasize the differences in the 
in vitro and in vivo effects of YKL-40 on cellular and systemic 
response. We can assume that YKL-40 might play various roles 
depending on the cell type. Changes in the extracellular matrix 
also affect YKL-40 synthesis. Microarray gene expression 
analysis determined that YKL-40 was overexpressed 4.4 fold 
in dedifferentiated human fetal chondrocytes in comparison 
with differentiated chondrocytes (26).
The level of YKL-40 secreted by normal cartilage explants 
is low during the first days of culture but after a few days 
increases significantly. YKL-40 production is also induced by 
cartilage resection or by removal of chondrocytes from their 
native environment (20). 
A study on the expression of YKL-40 in mouse mammary 
tissue found that YKL-40 was expressed feebly prior to and 
during pregnancy and lactation and increased during mammary 
gland involution, which is characterized by intensive tissue 
remodeling (27).
The exact function of YKL-40 continues to be unknown and 
specific receptor for YKL-40 has not been yet identified. It has 
been suggested that it probably plays a role in cell proliferation 
and differentiation (28). Other researchers revealed that YKL-
40 ensured protection against apoptosis during mammary 
involution (29) or preserved the extracellular matrix during 
tissue remodeling via suppression of different types of matrix 
metalloproteinases (30).
YKL-40 was supposed to induce signaling pathways 
in connective tissue and thus acts as a growth factor for 
fibroblasts, synovial cells and chondrocytes (28). Several 
studies showed a strong relationship between YKL-40 and 
vascular cells. YKL-40 functions as a migration and adhesion 
factor for these cells and activates formation of branching 
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tubules, hence could play a role in angiogenesis (31). 
There is growing body of evidence that increased expression 
and secretion of YKL-40 are associated with the pathogenesis 
of multiple human diseases. 
YKL-40 in normaL conditions
Cell expression of YKL-40
Intensive expression of mRNAYKL-40 is observed in all germ 
layers of human embryos, which are characterized with rapid 
proliferation and differentiation. YKL-40 protein is present 
in high concentrations during development of cartilage, bone, 
joints, and muscles (32). In normal adult human tissue, YKL-
40 is intensely expressed in mast cells, polymorphonuclear 
granulocytes, basal epithelial cells and neurons (33).
Serum levels of YKL-40 
There is no fixed reference value for YKL-40 in healthy per-
sons. It has been determined that the level of the glycoprotein 
increased with age and it is essential to use an identical age-
matched control group (34). Johansen suggested that changes 
in serum YKL-40 concentration higher than 20% should be 
considered as elevated serum values (3). It was determined that 
serum YKL-40 was stable in healthy subjects for short-term as 
well as for long-term sampling periods of up to 3 years (35).
Recently published levels of YKL-40 in healthy people 
differ among populations. The median serum concentration of 
the protein is around 43 ng/ml in Danish healthy individuals 
(35), while in the Turkish and Japanese population it is higher 
(5,36). This difference could be explained with the fact that 
some studies use serum and other plasma samples. Various 
immunoassays (ELISA, RIA) also could give divergent YKL-
40 levels. 
YKL-40 is not investigated in detail in Bulgaria yet. Our 
research is the first to reveal data for circulating YKL-40 in 
healthy Bulgarian subjects. We determined that the median 
serum value of YKL-40 in 40 healthy people, aged 53.69 ± 
3.30, was 84.19±11.39 ng/ml (37). The comparative data about 
serum YKL-40 concentrations in different healthy populations 
is included in Table 1.
YKL-40 in joint diseases
It is hypothesized that YKL-40 participates in acute and 
chronic inflammation, based on the fact that this glycoprotein 
is over-expressed in pathological conditions associated with 
active inflammatory processes. 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease of 
unknown etiology characterized by symmetrical synovial 



















Figure 1. Inducers and inhibitors of YKL-40 secretions in vitro.
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position as risk factors for RA is the linkage to MHC class 
II antigens HLA-DRB1 404 and HLA-DRB1 401 (42). It is 
discovered that YKL-40 contains HLA-DR4 binding motifs, 
so it is supposed to act as an autoantigen in RA (43). 
Reliable biomarkers of joint inflammation and destruction in 
RA patients are proteins released by cells in synovial fluid and 
serum. Some researchers have observed a 10-fold increase in 
the concentration of YKL-40 in synovial fluid in comparison 
with serum levels in RA patients. A significant relation between 
glycoprotein levels in serum and synovial fluid was detected 
in different populations with RA (44,45). It is suggested that 
YKL-40 in synovial fluid and serum might reflect cartilage 
degradation and synovial inflammation in RA (3,46).
The data about the importance of serum YKL-40 as a 
novel biomarker for the risk of progression of joint damage in 
patients with RA is contradictory. Some authors assume that 
it could be useful as a serious parameter in disease diagnosis 
and monitoring (36), other disagree with this statement (47). 
As mentioned above, YKL-40 is implicated in the process 
of angiogenesis (31), which is also essential in nourishing 
synovial tissue and has a central role in synovial inflammation 
and pannus formation (48). 
Recent mmunohistochemical study found that YKL-40 was 
expressed by polymorphonuclear cells in the synovial fluid of 
RA patients (48). This observation might provide another view 
on the inflammatory process and disease activity in comparison 
with conventional parameters. In this context, we suppose that 
YKL-40 may stimulate angiogenesis or acts as growth factor 
for chondrocytes and/or synovial fibroblasts. The levels of 
YKL-40 in inflammatory joint arthritis are presented in Table 2. 
Our investigation of RA patients showed a significant 
elevation of serum and synovial YKL-40 levels (48), strongly 
correlated with conventional parameters such as C-reactive 
protein and erythrocyte sedimentation rate. We determined 
that YKL-40 level in synovial fluid was significantly higher 
compared to the serum level and there was a positive 
correlation between them. We used sonography as a technique 
more sensitive for detecting lesions than conventional 
radiography. This is the first study that demonstrated a 
relationship between YKL-40 levels and ultrasonographic 
examinations. We suggested that the increased concentration in 
serum and synovial fluid of YKL-40 may indicate destructive 
changes in the cartilage (37).
Osteoarthritis 
Degraded cartilage and inflammed or thickened synovial 
tissue are the major manifestations of osteoarthritis (OA) 
(56). Several studies determined increased serum and syno-
vial YKL-40 levels in patients with severe OA compared to 
healthy subjects (5,48).  Zivanovic et al also suggested that 
YKL-40 could be used as a biomarker of joint damage in knee 
osteoarthritis (50). Other researchers did not detect YKL-40 
mRNA expression in normal human cartilage chondrocytes, 
while there were increased levels of the glycoprotein in 
articular cartilage from OA patients (51). High serum and 
synovial YKL-40 concentrations might reflect joint degrada-
tion and synovial inflammation (3). An association between 
the number of YKL-40 positive cells and the severity of the 
synovitis was also observed (36). 
It was demonstrated that YKL-40 bound to partially 
acetylated chito-oligosaccharides acted as a growth factor 
for chondrocytes in culture (57). They revealed that these 
biomaterials could benefit the symptoms of inflammatory 
joint disorders more effectively than glucosamine. Likewise, 
YKL-40 itself may be a target for a novel therapeutic approach 
in OA (57).
Psoriatic and gout arthritis 
Psoriatic and gout arthritis are chronic inflammatory disorders, 
which have different etiology but manifest common clinical 
features. The pathogenesis of these diseases is still incom-
pletely revealed. The pathophysiological role of synovium and 
the regulation of cytokine biosynthesis are just beginning to 
be elucidated (58,59). There are only two small scale studies 
on YKL-40 in psoriatic arthritis, which determine significantly 
higher serum YKL-40 levels in patients compared to healthy 
people (52,53). 
Our preliminary results show that in all patients with 
psoriatic and gout arthritis the concentration of serum YKL-
Table 1. Serum YKL-40 levels (ng/ml) in different  
healthy populations
№ Population Serum YKL-40 levels References №
1 Danish 43 35
2 French 59 38
3 Chinese 61.1 39
4 Bulgarian 84.19 37
5 Japanese 101.7 40
6 Turkish 114 5
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YKL-40 in synovial  
fluid
References №
1 Knee osteoarthritis 55 131.35 ± 90.91 - 5
2 Knee osteoarthritis 88 138.22 ± 48.88 - 50
3 Knee osteoarthritis 39 73 (26-565) 119 (274-2600) 51
4 Hip osteoarthritis 45 67.5 (33-343) - 38
5 Rheumatoid arthritis 308 86 - 4
6 Rheumatoid arthritis 40 246.18 ± 209.36 509.77 ± 375.56 37
7 Rheumatoid arthritis 20 87 (20-218) 212 (485-6850) 51
8 Spondyloarthritis 49 74  (14-572) - 52
9 Psoriatic arthritis 42 112 53
10 Psoriatic arthritis 14 128.06 353.6 54
11 Gout arthritis 7 277.27 ± 126.95 769.61 ± 61.02 55
40 is remarkably elevated. The synovial level of the protein is 
significantly higher in comparison with the serum value. No 
evident relationship between the concentration of YKL-40 and 
proinflammatory cytokines in patients with psoriatic and gout 
arthritis was established. Whereas a strong association between 
serum and synovial levels of YKL-40 and serum TNF-α and 
IL-1β in patients with RA patients was detected. We suggest 
that the different concentration of YKL-40 in the three types 
of arthritis might reflect specific pathogenetic routes in these 
inflammatory joint diseases (55). 
concLUsion
YKL-40 is expressed and secreted by inflammatory cells and 
arthritic chondrocytes. Significantly increased expression of 
both YKL-40 mRNA and protein in human tissues is found in 
pathological conditions with acute or chronic inflammation. 
The relationship between the concentration of YKL-40 with 
conventional parameters, proinflammatory cytokines and 
sonograhic examinations indicates that YKL-40 is associated 
with progression of inflammatory processes. Based on the 
recently published information about YKL-40 in inflamma-
tory joint processes and our own studies, we could conclude 
that the YKL-40 might be a useful biomarker for diagnosis 
and monitoring of disease activity in rheumatic joint arthritis. 
The complete prognostic value of YKL-40 in clinical practice 
remains to be elucidated. 
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